SMAD2/3 Phosphorylation Is Downregulated in T Cells in HIV-Infected Patients

Area of Science:

• Immunology
• Molecular Biology
• Virology

Background:

• Persistent inflammation is a hallmark of HIV infection, contributing to immune exhaustion and non-AIDS-defining events.
• Transforming growth factor β (TGF-β) is typically anti-inflammatory, yet its high levels coexist with chronic inflammation in HIV patients, posing a paradox.
• The exact mechanisms linking TGF-β signaling to chronic inflammation in HIV remain unclear.

Purpose of the Study:

• To investigate the status of the TGF-β/SMAD2/3 signaling pathway in HIV-infected patients.
• To explore the potential role of this pathway's disturbance in the pathogenesis of HIV-related chronic inflammation.

Main Methods:

• Comparative analysis of phosphorylated SMAD2/3-positive T cells (total CD3+, CD3+CD8+, and CD3+CD8- subsets) between HIV-infected patients and healthy subjects.
• Flow cytometry was utilized to quantify cell populations.

Main Results:

• HIV-infected patients exhibited a significantly lower proportion of phosphorylated SMAD2/3-positive cells compared to healthy individuals.
• This reduction was observed across total CD3+ T cells and specific subsets (CD3+CD8+ and CD3+CD8- T cells).

Conclusions:

• The findings indicate an inhibition of SMAD2/3 phosphorylation in HIV-infected patients.
• Disturbance in the TGF-β/SMAD2/3 signaling pathway is implicated as a potential contributor to chronic inflammation during HIV infection.
• This suggests a novel therapeutic target for managing HIV-associated inflammation.